Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…
aTyr Pharma Shares Ascend As FDA Grants Fast Track Status To Lung Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease.
$1.4 Million Bet On This Healthcare Stock? 4 Penny Stocks Insiders are Buying
U.S. stock futures traded higher this morning on Thursday after closing slightly higher on Wednesday. Investors, meanwhile, focused on some notable insider trades.
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell
• Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Earnings Outlook For aTyr Pharma
aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement.
Analysts estimate that aTyr Pharma will report an earnings per share (EPS) of $-0.33.
aTyr Pharma Announces FDA Orphan Drug Designation For Efzofitimod (ATYR1923) For Treatment Of Systemic Sclerosis
SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways,